Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) P. Fenaux et al.   ANNALS OF ONCOLOGY

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

(2014) G. Garcia-Manero et al.   CLINICAL CANCER RESEARCH

Myelodysplastic syndromes

(2014) Lionel Adès et al.   LANCET

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors

(2014) Kathy L. McGraw et al.   PLoS One

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

(2014) M Tobiasson et al.   Blood Cancer Journal

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

(2013) V Sardnal et al.   LEUKEMIA

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

(2012) R. S. Komrokji et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis

(2011) A. Narla et al.   BLOOD

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

(2011) David Sibon et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome

(2011) Azra Raza et al.   CANCER

Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

(2010) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment

(2009) M. A. Sekeres et al.   BLOOD

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

(2008) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

(2008) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

(2007) S. Park et al.   BLOOD